Further characterization of cyclophosphamide resistance: Expression of CD95 and of bcl-2 in a CML cell line

Reinhold Munker, Shourong Zhao, Shuwei Jiang, Virginia Snell, Michael Andreeff, Börje S. Andersson

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

Drug resistance is a common cause of treatment failure in oncology. In addition to the resistance caused by over-expression of p-glycoprotein and similar molecules other mechanisms are involved in the selection or induction of drug resistant tumor cells. In this study, we characterized a CML cell line made resistant to cyclophosphamide (KBM7-B5-1803) further for the expression of apoptosis promoting and inhibiting molecules. We found that KBM7-B5-1803 has a 3-4-fold over-expression of the receptor CD95 (Fas/Apo-1) compared with the parent line. The regulation of CD95 by cytokines was comparable to other types of cells. Despite the inducibility and over-expression of CD95, CD95 failed to trigger apoptosis in both the parent and the drug resistant line. The drug resistant line has a particular pattern of the expression of bcl-2 family members: bcl-2 protein and message were expressed to a similar extent, however, compared with the parent line, the message for bclx short was decreased. P-glycoprotein was not expressed in either cell line. Taken together we show here in a leukemia cell line that the phenotype of cyclophosphamide resistance is associated with a particular pattern of apoptosis-related molecules.

Original languageEnglish (US)
Pages (from-to)1073-1077
Number of pages5
JournalLeukemia Research
Volume22
Issue number11
DOIs
StatePublished - Nov 1998

Keywords

  • Bcl-2
  • CD95/Fas
  • Cyclophosphamide

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Further characterization of cyclophosphamide resistance: Expression of CD95 and of bcl-2 in a CML cell line'. Together they form a unique fingerprint.

Cite this